• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Aeterna Zentaris - Articles and news items

zoptrex

Aeterna Zentaris’ Zoptrex granted licensing agreement for Australia and New Zealand

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

Zoptrex, a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer…

license-asia-cancer-drug

Asian licensing deals for Ergomed and Aeterna Zentaris’ endometrial cancer drug

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

Aeterna Zentaris signed an exclusive license agreement with affiliates of Orient EuroPharma for its lead anti-cancer compound, zoptrex, for the initial…

aeterna-zentaris-macrilen

Aeterna Zentaris’ confirmatory Phase 3 study for Macrilen in AGHD meets EMA’s study-design expectations

Industry news / 27 May 2015 / Victoria White

Aeterna Zentaris has received advice from the EMA regarding the development plan for the new confirmatory Phase 3 clinical study of Macrilen in AGHD…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +